Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy

Archives of Ophthalmology

Volumn 130, Issue 6, 2012, Pages 677-684

  Gulati, Vikas ^a   Fan, Shan ^a   Zhao, Min ^a   Maslonka, Matthew A ^a   Gangahar, Chiraag ^a   Toris, Carol B ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE; LATANOPROST; TIMOLOL MALEATE;

ADULT; ANTERIOR EYE CHAMBER DEPTH; AQUEOUS HUMOR FLOW; AQUEOUS HUMOR OUTFLOW; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA THICKNESS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EVENING DOSAGE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NIGHT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VENOUS PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; BLOOD PRESSURE; CARBONIC ANHYDRASE INHIBITORS; CIRCADIAN RHYTHM; CORNEA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FLUOROPHOTOMETRY; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; SPHYGMOMANOMETERS; SULFONAMIDES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR;

EID: 84862199855     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.2573     Document Type: Article

References (50)

1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 12: baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol. 2002;134(4):499-512.
2. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714-720. (Pubitemid 34620349)
3. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440.
4. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study, 7: results. Am J Ophthalmol. 1995;120(6):718-731.
5. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT), 2: results of argon laser trabeculoplasty versus topical medicines. Ophthalmology. 1990;97(11):1403-1413.
6. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10):1268-1279. (Pubitemid 36105431)
7. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115(1):45-49. (Pubitemid 27034930)
8. Zimmerman TJ, Boger WP III. The β-adrenergic blocking agents and the treatment of glaucoma. Surv Ophthalmol. 1979;23(6):347-362. (Pubitemid 9199790)
9. Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res. 1998;17(3):291-312. (Pubitemid 28342386)
10. Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:519-525.
11. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128(1):8-14. (Pubitemid 29315757)
12. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113(12):1514-1517.
13. Liu H, Fan S, Gulati V, et al. Aqueous humor dynamics during the day and night in healthy mature volunteers. Arch Ophthalmol. 2011;129(3):269-275.
14. Fan S, Hejkal JJ, Gulati V, Galata S, Camras CB, Toris CB. Aqueous humor dynamics during the day and night in volunteers with ocular hypertension. Arch Ophthalmol. 2011;129(9):1162-1166.
15. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci. 1984;25(6):776-778. (Pubitemid 14082992)
16. Schenker HI, Yablonski ME, Podos SM, Linder L. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol. 1981;99(7):1212-1216. (Pubitemid 11087067)
17. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 1982;93(2):232-237. (Pubitemid 12165868)
18. Brubaker RF, Nagataki S, Bourne WM. Effect of chronically administered timolol on aqueous humor flow in patients with glaucoma. Ophthalmology. 1982;89 (3):280-283. (Pubitemid 12143091)
19. Yamazaki Y, Miyamoto S, Sawa M. Effect of MK-507 on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 1994;38(1):92-96. (Pubitemid 24119333)
20. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 α analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993; 100(9):1297-1304. (Pubitemid 23274021)
21. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects: a crossover study. Ophthalmology. 2008;115(5):790-795.e4. doi:10.1016/j.ophtha.2007.07.002.
22. Mishima HK, Kiuchi Y, Takamatsu M, Rácz P, Bito LZ. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol. 1997;41(suppl 2):S139-S144. (Pubitemid 27154538)
23. McCannel CA, Heinrich SR, Brubaker RF. Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans. Graefes Arch Clin Exp Ophthalmol. 1992; 230(6):518-520.
24. Koskela T, Brubaker RF. Apraclonidine and timolol: combined effects in previously untreated normal subjects. Arch Ophthalmol. 1991;109(6):804-806.
25. Stamper RL, Lieberman MF, Drake MV. Becker-Schaffer's Diagnosis and Therapy of the Glaucomas. St Louis, MO: Mosby; 1999:101-113.
26. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978; 27(2):135-142. (Pubitemid 9004152)
27. Zeimer RC, Gieser DK, Wilensky JT, Noth JM, Mori MM, Odunukwe EE. A practical venomanometer: measurement of episcleral venous pressure and assessment of the normal range. Arch Ophthalmol. 1983;101(9):1447-1449. (Pubitemid 13000428)
28. Toris CB, Zhan GL, Yablonski ME, Camras CB. Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide. J Glaucoma. 2004; 13(3):210-215. (Pubitemid 38669071)
29. Wang RF, Serle JB, Podos SM, Sugrue MF. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991;109(9):1297-1299.
30. Toris CB, Yablonski ME, Wang YL, Hayashi M. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 1995; 61(6):649-657. (Pubitemid 26017011)
31. Eisenlohr JE, Langham ME, Maumenee AE. Manometric studies of the pressure-volume relationship in living and enucleated eyes of individual human subjects. Br J Ophthalmol. 1962;46(9):536-548.
32. Blondeau P, Tétrault JP, Papamarkakis C. Diurnal variation of episcleral venous pressure in healthy patients: a pilot study. J Glaucoma. 2001;10(1):18-24. (Pubitemid 32151790)
33. Sultan M, Blondeau P. Episcleral venous pressure in younger and older subjects in the sitting and supine positions. J Glaucoma. 2003;12(4):370-373. (Pubitemid 37169659)
34. Brubaker RF. Measurement of uveoscleral outflow in humans. J Glaucoma. 2001; 10(5)(suppl 1):S45-S48.
35. Johnson TV, Fan S, Zhan G, Camras CB, Toris CB. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment. J Glaucoma. 2010;19(6):356-364.
36. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993;111(10):1343-1350. (Pubitemid 23296778)
37. MK-507 Clinical Study Group. Long-term glaucoma treatment with MK-507, dorzolamide, a topical carbonic anhydrase inhibitor. J Glaucoma. 1995;4(1):6-10.
38. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004; 138(3):389-395. (Pubitemid 39208565)
39. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41(9):2566-2573. (Pubitemid 30624384)
40. Liu JH, Medeiros FA, Slight JR, Weinreb RN. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology. 2009;116(3):449-454.
41. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47(7):2917-2923. (Pubitemid 351639767)
42. Quaranta L, Miglior S, Floriani I, Pizzolante T, Konstas AG. Effects of the timololdorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma. Invest Ophthalmol Vis Sci. 2008;49(10):4226-4231.
43. Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2003;121(4):453-457. (Pubitemid 36427631)
44. Konstas AG, Holló G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010;94(2):209-213.
45. Nakamoto K, Yasuda N. Effect of carteolol hydrochloride on 24-hour variation of intraocular pressure in normal-tension glaucoma. Jpn J Ophthalmol. 2010; 54(2):140-143.
46. Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113(2):239-246. (Pubitemid 43170772)
47. Sit AJ, Weinreb RN, Crowston JG, Kripke DF, Liu JH. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol. 2006; 141(6):1131-1133. (Pubitemid 43831052)
48. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008; 53(suppl 1):S107-S120.
49. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102(3):456-461.
50. Liu JH, Weinreb RN. Monitoring intraocular pressure for 24 h. Br J Ophthalmol. 2011;95(5):599-600.